［1］ Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment［J］. Prog Clin Bid Res, 1994, 385: 363-369.
［2］Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada［J］. J Natl Cancer Inst, 2000, 92(3): 205-216.
［5］Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children′s Cancer Group pilot study［J］. J Clin Oncol, 1993, 11(11): 2226-2233.
［7］Garaventa A, Parodi S, De Bernardi B,Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry［J］. Eur J Cancer, 2009, 45(16): 2835-2842.
［8］Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma［J］. J Pediatr Hematol Oncol, 2004, 26(4): 227-232.
［9］Miles SA, Sandler AD. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma［J］. Adv Drug Deliv Rev, 2009, 61(3): 275-282.
［10］Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma［J］. Mol Ther, 2007, 15(4): 825-833.
［11］Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis［J］. Cancer Lett, 2005, 228(1-2): 171-179.
